Olaris^® uses high-powered metabolomics profiling tools and proprietary machine learning to identify Biomarkers of Response (BoRs) that stratify patients into optimal treatment groups, removing the guesswork from medicine. By discovering metabolite biomarkers that correlate with treatment efficacy -- BoRs -- we seek to get the right drug at the right dose to the right patient at the right time. Our BoRs will optimize outcomes and bring precision medicine to patients across indications, including in solid-organ transplants, oncology, and neurodegeneration. 

Olaris^® is focused on three main areas to serve the clinical and biopharma community:

1. Response Monitoring: to assess, alone or in combination, treatment response, immune system response, and risk of treatment complications

2. Treatment Selection: to provide clinicians with predictive tools to select optimal treatment

3. Screening: to diagnose burdensome diseases earlier than standard-of-care methods